Sanofi Sees Dupixent As Just The Start Of COPD Transformation
Itepekimab Also In Development
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.
